NOVN

Novan, Inc. [NOVN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NOVN Stock Summary

In the News

03:07 29 Mar 2024 NOVN

Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript

Novan, Inc. (NASDAQ:NOVN ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President & Chief Executive Officer John Donofrio - Executive Vice President & Chief Operating Officer John Gay - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Jeff Jones - Oppenheimer Jonathan Aschoff - Roth Capital Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello and welcome to the Novan Inc. Quarterly Update Conference Call and Webcast.

09:05 29 Mar 2024 NOVN

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

09:00 29 Mar 2024 NOVN

Novan to Report Full Year 2022 Financial Results on March 30, 2023

DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

08:30 29 Mar 2024 NOVN

Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference

Presentation with live webcast today, March 14th at 10:40 AM ET Presentation with live webcast today, March 14th at 10:40 AM ET

08:05 29 Mar 2024 NOVN

Novan to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET

02:40 29 Mar 2024 NOVN

Novan, Inc. (NOVN) Q3 2022 Earnings Call Transcript

Novan, Inc. (NASDAQ:NOVN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President, and Chief Executive Officer John Gay - Chief Financial Officer John Donofrio - Chief Operating Officer and President, EPI Health Conference Call Participants Jeff Jones - Oppenheimer Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

10:29 29 Mar 2024 NOVN

Novan, Inc. (NOVN) CEO Paula Stafford on Q2 2022 Results - Earnings Call Transcript

Novan, Inc. (NASDAQ:NOVN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Paula Stafford - President, CEO & Chairwoman John Gay - CFO & Corporate Secretary John Donofrio - EVP, COO & President, EPI Health Conference Call Participants Jeff Jones - Oppenheimer Brian Dolliver - Brookline Capital Markets Jonathan Aschoff - ROTH Capital Partners Oren Livnat - H.C. Wainwright & Co. John Vandermosten - Zacks Small-Cap Research Jennifer Kim - Cantor Fitzgerald & Co. Operator Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast.

09:05 29 Mar 2024 NOVN

Novan to Report Second Quarter 2022 Financial Results on August 11, 2022

DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

09:05 29 Mar 2024 NOVN

Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology

– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum –

11:21 29 Mar 2024 NOVN

Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q1 2022 Results - Earnings Call Transcript

Novan, Inc. (NASDAQ:NOVN ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President and Chief Executive Officer John Donofrio - Chief Operating Officer, Novan and President, EPI Health John Gay - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital John Vandermosten - Zacks Jonathan Aschoff - Roth Capital Partners Operator Hello and welcome to the Novan, Incorporated Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

NOVN Financial details

Company Rating
Neutral
Market Cap
2.64M
Income
999K
Revenue
24.71M
Book val./share
-0.11
Cash/share
0.48
Dividend
-
Dividend %
-
Employees
90
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
2.46
Forward P/E
-
PEG
-0.23
P/S
0.11
P/B
-0.87
P/C
-
P/FCF
-0.07
Quick Ratio
0.6
Current Ratio
0.74
Debt / Equity
-1.36
LT Debt / Equity
-1.2
-
-
EPS (TTM)
0.12
EPS next Y
-
EPS next Q
-0.43
EPS this Y
-47.34%
EPS next Y
-
EPS next 5Y
-2346.26%
EPS last 5Y
-28.93%
Revenue last 5Y
31.56%
Revenue Q/Q
-71.38%
EPS Q/Q
-144.63%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
7.63%
Inst Trans
0.49%
ROA
1%
ROE
19%
ROC
-0.99%
Gross Margin
66%
Oper. Margin
-144%
Profit Margin
4%
Payout
-
Shs Outstand
28.02M
Shs Float
25.52M
-
-
-
-
Target Price
-
52W Range
0.082-3.33
52W High
-
52W Low
-
RSI
-
Rel Volume
6.68
Avg Volume
1.04M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.043374
-
-
Volatility
0.02%, 0.02%
Prev Close
-
Price
-
Change
-

NOVN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.321.710.430.171.07
Net income per share
-4.91-11.72-3.05-1.69-0.89
Operating cash flow per share
-11.1-7.57-3.14-1.45-1.4
Free cash flow per share
-11.53-7.73-3.21-1.98-1.6
Cash per share
3.185.223.632.760.56
Book value per share
2.02-9.060.31.070.21
Tangible book value per share
1.99-9.090.291.07-1.22
Share holders equity per share
2.02-9.060.31.070.21
Interest debt per share
3.512.390.10.50.24
Market cap
21.41M82.96M80.33M71.16M32.15M
Enterprise value
21.24M75.51M45.41M27.69M23.76M
P/E ratio
-1.69-2.7-2.66-2.47-1.64
Price to sales ratio
3.5718.5319.0925.221.36
POCF ratio
-0.75-4.17-2.59-2.87-1.04
PFCF ratio
-0.72-4.09-2.53-2.1-0.91
P/B Ratio
4.12-3.4926.983.886.98
PTB ratio
4.12-3.4926.983.886.98
EV to sales
3.5416.8710.799.811.01
Enterprise value over EBITDA
-0.8-2.66-1.89-0.91-0.7
EV to operating cash flow
-0.74-3.8-1.46-1.12-0.77
EV to free cash flow
-0.71-3.72-1.43-0.82-0.68
Earnings yield
-0.59-0.37-0.38-0.41-0.61
Free cash flow yield
-1.39-0.24-0.39-0.48-1.09
Debt to equity
1.54-0.260.320.470.85
Debt to assets
0.30.220.020.120.04
Net debt to EBITDA
0.010.261.451.430.25
Current ratio
1.031.225.064.850.91
Interest coverage
-27.28-15.34K00-24.37
Income quality
2.260.651.060.830.99
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.922.332.684.370
Research and developement to revenue
3.855.624.717.230.68
Intangibles to total assets
00000.35
Capex to operating cash flow
0.040.020.020.370.14
Capex to revenue
-0.18-0.09-0.15-3.21-0.18
Capex to depreciation
-0.67-0.21-0.55-26.31-1.54
Stock based compensation to revenue
0.370.410.310.10.08
Graham number
14.9248.894.556.392.04
ROIC
0.342.74-7.91-0.95-1.77
Return on tangible assets
-0.48-1.06-0.65-0.42-0.33
Graham Net
-5.03-14.88-0.680.06-2.56
Working capital
289K2.83M35.31M42.98M-4.03M
Tangible asset value
5.12M-23.86M2.9M18.24M-26.93M
Net current asset value
-11.81M-37.16M155K3.49M-43.36M
Invested capital
1.54-0.260.320.470.85
Average receivables
0209.5K2.64M4.67M13.24M
Average payables
864.5K1.43M1.4M1.68M7.93M
Average inventory
0-209.5K-2.64M-1.2M1.83M
Days sales outstanding
034.16421.81578.54340.16
Days payables outstanding
19.823.2300677.12
Days of inventory on hand
0-6.080059.16
Receivables turnover
010.680.870.631.07
Payables turnover
18.4415.71000.54
Inventory turnover
0-60.08006.17
ROE
-2.441.29-10.13-1.57-4.25
Capex per share
-0.43-0.16-0.07-0.53-0.19

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.10.30.210.480.11
Net income per share
-0.72-0.45-0.11.21-0.54
Operating cash flow per share
0.04-0.55-0.39-0.5-0.16
Free cash flow per share
-0.01-0.64-0.4-0.55-0.16
Cash per share
1.881.850.610.560.48
Book value per share
0.310.610.280.21-0.11
Tangible book value per share
-1.65-1.15-1.04-1.22-1.3
Share holders equity per share
0.310.610.280.21-0.11
Interest debt per share
1.11.040.190.180.16
Market cap
74.19M47.1M45.74M32.15M33.95M
Enterprise value
59.33M30.23M34.9M23.76M25.26M
P/E ratio
-1.37-1.31-4.680.3-0.6
Price to sales ratio
39.217.668.973.0711.33
POCF ratio
96.85-4.24-4.85-2.89-7.99
PFCF ratio
-457.95-3.63-4.65-2.64-7.95
P/B Ratio
12.613.856.776.98-12.01
PTB ratio
12.613.856.776.98-12.01
EV to sales
31.364.916.852.278.43
Enterprise value over EBITDA
-4.55-3.81-4.04-7.96-2.02
EV to operating cash flow
77.45-2.72-3.7-2.14-5.94
EV to free cash flow
-366.22-2.33-3.55-1.95-5.91
Earnings yield
-0.18-0.19-0.050.83-0.42
Free cash flow yield
0-0.28-0.22-0.38-0.13
Debt to equity
3.511.670.60.85-1.36
Debt to assets
0.180.180.050.040.05
Net debt to EBITDA
1.142.131.262.810.69
Current ratio
1.251.40.970.910.74
Interest coverage
-100.2-14.38-15.15-49.4-48.62
Income quality
-0.061.251.563.670.3
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00003.35
Research and developement to revenue
2.550.510.840.361.61
Intangibles to total assets
0.330.310.390.350.39
Capex to operating cash flow
-1.210.170.040.10.01
Capex to revenue
-0.49-0.3-0.08-0.1-0.01
Capex to depreciation
-4.26-2.35-0.45-1.25-0.03
Stock based compensation to revenue
0.20.070.10.050.14
Graham number
2.252.470.792.381.15
ROIC
-0.44-0.24-0.262.68-2.77
Return on tangible assets
-0.18-0.11-0.050.45-0.29
Graham Net
-3.08-2.49-2.04-2.56-2.26
Working capital
11.71M17.8M-1000K-4.03M-11.22M
Tangible asset value
-31.07M-23.19M-25.33M-26.93M-33.88M
Net current asset value
-47.49M-40.09M-41.88M-43.36M-49.94M
Invested capital
3.511.670.60.85-1.36
Average receivables
10.24M17.12M16.55M18.44M17.92M
Average payables
3.46M5.75M5.42M8.88M14.01M
Average inventory
1.97M1.52M1.37M1.19M1.16M
Days sales outstanding
761.72266.46262.78189.17415.63
Days payables outstanding
2.08K232.79254.63394.881K
Days of inventory on hand
645.7353.7273.6334.578.16
Receivables turnover
0.120.340.340.480.22
Payables turnover
0.040.390.350.230.09
Inventory turnover
0.141.681.222.611.15
ROE
-2.3-0.74-0.365.774.99
Capex per share
-0.05-0.09-0.02-0.050

NOVN Frequently Asked Questions

What is Novan, Inc. stock symbol ?

Novan, Inc. is a US stock , located in Durham of Ca and trading under the symbol NOVN

What is Novan, Inc. stock quote today ?

Novan, Inc. stock price is $- today.

Is Novan, Inc. stock public?

Yes, Novan, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap